Shots:
- Sun Pharma has launched Leqselvi (deuruxolitinib; 8mg) for the treatment of pts with severe alopecia areata in the US
- FDA Approval was based on 2 P-III (THRIVE-AA1 & THRIVE-AA2) trials that assessed the scalp hair regrowth using the SALT score with Leqselvi (8 or 12mg, BID) vs PBO in adults (n=1223; 18-65yrs.) with severe alopecia areata post 24wks. across the US, Canada & EU
- In trials, Leqselvi showed rapid efficacy, with one third of pts regaining nearly full scalp hair by Wk. 24, & 3% achieving >80% scalp coverage as early as 8wks.
Ref: Prnewswire | Image: Sunpharma | Press Release
Related News:- Sun Pharma to Acquire Checkpoint Therapeutics For ~$355M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
